RNF7 Facilitated the Tumorigenesis of Pancreatic Cancer by Activating PI3K/Akt Signaling Pathway

被引:3
作者
Hua, Hao [1 ,2 ]
Xie, Huahua [1 ,2 ]
Zheng, Jian [1 ,2 ]
Lei, Linhan [1 ,2 ]
Deng, Zilei [1 ,2 ]
Yu, Chao [1 ,2 ]
机构
[1] Guizhou Med Univ, Dept Hepat Biliary Pancreat Surg, Affiliate Hosp, Guiyang, Guizhou, Peoples R China
[2] Guizhou Med Univ, Sch Clin Med, Guiyang, Guizhou, Peoples R China
关键词
E3 UBIQUITIN LIGASE; DEVELOPMENTALLY-REGULATED KINASE; INDUCE APOPTOSIS; TUMOR-GROWTH; CELL-GROWTH; EXPRESSION; PROGRESSION; PROTEIN; GENE; SAG;
D O I
10.1155/2023/1728463
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
RING finger protein-7 (RNF7) functions as a positive regulator in the progression of multiple malignancies. However, the underlying mechanism by which RNF7 contributes to pancreatic cancer (PC) is lacking. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to test the level of RNF7expression in PC cell lines and tissues. The role of RNF7 in PC tumorigenesis was analyzed by Cell Counting Kit-8 (CCK-8). 5-Ethynyl-20-deoxyuridine (EdU), wound-healing/Transwell assays, as well as a subcutaneous tumorigenesis model were constructed to assess the role of RNF7 in PC cells. The association between RNF7 and PI3K/Akt signaling were assessed by western blot and further confirmed by rescue experiments. The PC patients with upregulated expression of RNF7 had poor survival. Overexpression of RNF7 significantly facilitated PC proliferative and migrative and invasive properties in vitro and vivo; however, knockdown of RNF7exhibited the opposite results. Mechanistically, RNF7 promoted PANC-1 and SW1990 cell growth through impacting the activation of the PI3K/Akt signaling pathway. Our data demonstrated that RNF7 promoted PC tumorigenesis via activating the PI3K/Akt signaling pathway and might be regarded as one of the potential therapies to PC.
引用
收藏
页数:17
相关论文
共 47 条
  • [1] NF-κB Pathway in Autoinflammatory Diseases: Dysregulation of Protein Modifications by Ubiquitin Defines a New Category of Autoinflammatory Diseases
    Aksentijevich, Ivona
    Zhou, Qing
    [J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [2] The Genetic Basis for Cancer Treatment Decisions
    Dancey, Janet E.
    Bedard, Philippe L.
    Onetto, Nicole
    Hudson, Thomas J.
    [J]. CELL, 2012, 148 (03) : 409 - 420
  • [3] Ror2 as a Therapeutic Target in Cancer
    Debebe, Zufan
    Rathmell, W. Kimryn
    [J]. PHARMACOLOGY & THERAPEUTICS, 2015, 150 : 143 - 148
  • [4] Breast cancer statistics and markers
    Donepudi, Mallika Siva
    Kondapalli, Kasturi
    Amos, Seelam Jeevan
    Venkanteshan, Pavithra
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2014, 10 (03) : 506 - 511
  • [5] Duan HJ, 1999, MOL CELL BIOL, V19, P3145
  • [6] Duan HJ, 2001, MOL CARCINOGEN, V30, P37, DOI 10.1002/1098-2744(200101)30:1<37::AID-MC1011>3.0.CO
  • [7] 2-7
  • [8] The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
    Engelman, Jeffrey A.
    Luo, Ji
    Cantley, Lewis C.
    [J]. NATURE REVIEWS GENETICS, 2006, 7 (08) : 606 - 619
  • [9] PI3K and cancer: lessons, challenges and opportunities
    Fruman, David A.
    Rommel, Christian
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (02) : 140 - 156
  • [10] SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-jun/AP1 and IκB-α/NF-κB
    Gu, Qingyang
    Bowden, G. Tim
    Normolle, Daniel
    Sun, Yi
    [J]. JOURNAL OF CELL BIOLOGY, 2007, 178 (06) : 1009 - 1023